CCR2 and Hepatic fibrosis: Cenicriviroc, an oral inhibitor of CCR2 and CCR5, significantly reduced the recruitment of hepatic Ly6C+ monocytes, inhibited alcohol-induced steatohepatitis and ameliorated liver fibrosis in mice [177,178].